Search

Your search keyword '"Wu, Jiahui"' showing total 847 results
Start Over Author "Wu, Jiahui" Publication Type Academic Journals
847 results on '"Wu, Jiahui"'

13. Simulation study on transient stability of AC systems considering the connected power-controlled grid-forming converters

Author

DAN Yangqing, HUANG Ying, HAN Lianshan, WANG Chenxuan, WU Jiahui, LIU Qing, and XU Zheng

Subjects
power-controlled gfm converter, gfl converter, transient stability, equivalent inertia coefficient, damping coefficient, Electrical engineering. Electronics. Nuclear engineering, TK1-9971
Abstract

To investigate the evolution trend of transient stability of power-controlled grid-forming （GFM） converters connected to AC systems， generators are replaced with power-controlled grid-forming （GFM） converters and grid-following （GFL） converters of equal capacity using the IEEE 39-bus AC test system. Additionally， the number of connections and integration positions in the AC system are varied for electromagnetic transient simulations. The results indicate that power-controlled grid-forming converters exhibit superior transient stability enhancement capabilities in the integration area， especially when the replaced generators are adjacent. As the proportion of such converters in the system increases， the system’s transient stability strengthens. Furthermore， higher equivalent inertia coefficients within power-controlled GFM converters lead to weaker synchronous stability of the system， whereas higher internal damping coefficients enhance synchronous stability.

Published
2024
Full Text
View/download PDF

21. Current status and treatment direction of the immune microenvironment of castration-resistant prostate cancer

Author

YANG Wenbo, ZHANG Bin, WU Jiahui, CUI Jie

Subjects
castration-resistant, prostate cancer, tumor immune microenvironment, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

With the rapid development of cancer immunology, more and more research focuses on the role of immune cells and signaling molecules in the tumor microenvironment. Prostate cancer is the second most common malignant tumor in men globally. With the increase in our population ages and screening rates, the incidence of prostate cancer in China is increasing. Androgen deprivation therapy (ADT) is a primary treatment for late-stage prostate cancer. However, most patients eventually progress to castration-resistant prostate cancer (CRPC) after ADT treatment. The median survival of CRPC patients has been less than two years. Although new treatment methods have emerged in recent years, and patient survival has improved, however, the overall prognosis still remains poor. Tumor immunotherapy works by stimulating or rebuilding the body's immune system to control and kill tumor cells. In recent years, immunotherapy has entered clinical research and rapidly developed into an effective tumor-treatment approach following surgery, radiotherapy, chemotherapy and targeted therapy. However, the effect of immunotherapy on CRPC patients is usually very poor. Therefore, the tumor microenvironment of CRPC has attracted many scholars' attention. Previous studies have suggested that CRPC generally has less immune infiltration, a relatively high immunosuppressive tumor microenvironment, such as low infiltration and activity of T cells, and high expressions of various immunosuppressive factors, such as cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1), etc., which is considered as an immune "cold" tumor. In addition to its own immune-inhibitory mechanisms, CRPC has complex immune evasion mechanisms that suppress immune cell activity or selectively express low immunogenic antigen to evade immune system recognition. Due to the particular immunosuppressive tumor microenvironment of CRPC, the effect of immunotherapy alone is often unsatisfactory. Therefore, the selection of appropriate immunotherapy strategies has become the key to improving the treatment effect of CRPC patients. This review summarized the mechanisms underlying immune cells in the immune microenvironment of CRPC tumors and their interactions with various cytokines in the context of immune checkpoint inhibitor therapy combined with ADT, chemotherapy, Sipuleucel-T tumor vaccines, chimeric antigen receptor-T (CAR-T) cell therapy, oncolytic virus therapy, or in combination with chemokine receptor antagonists, tyrosine kinase inhibitors, poly (ADP-ribose) polymerase (PARP) inhibitors and other treatments. In conclusion, the tumor immune microenvironment of CRPC is highly complex, and immunotherapy still faces many challenges. However, with the progress of technological advancements and research, some new immunotherapy options are being studied, and it is believed that tumor immunotherapy will bring better therapeutic effects to patients with CRPC in the future.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results